Literature DB >> 17472599

Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.

Phil Lee1, Liang Shu, Xiufeng Xu, Chuan Yue Wang, Min Soo Lee, Chia-Yih Liu, Jin Pyo Hong, Sandra Ruschel, Joel Raskin, Samuel A Colman, Gavan A Harrison.   

Abstract

The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in the acute treatment of major depressive disorder (MDD). In a randomized, double-blind trial of 8 weeks active treatment, patients with non-psychotic MDD were randomized to duloxetine 60 mg (n = 238) or paroxetine 20 mg (n = 240) once daily. Efficacy was primarily measured on change in the 17-item Hamilton Rating Scale for Depression (HAMD(17)) using a non-inferiority test with a margin of 2.2. Secondary efficacy measures included the HAMD(17) subscales, Hamilton Rating Scale for Anxiety, Clinical Global Impressions-Severity, Patient Global Impressions-Improvement, Somatic Symptoms Inventory and Visual Analog Scales (VAS) for pain. Safety measures included treatment-emergent adverse events (TEAE), vital signs, weight, laboratory analyses and electrocardiograms. Non-inferiority of duloxetine to paroxetine was demonstrated because the upper bound of the confidence interval for mean difference in HAMD(17) change (0.71) was less than the non-inferiority margin. Secondary efficacy end-points did not differ significantly between treatments with the exception of VAS back pain, where the pooled mean was lower in the duloxetine group (17.1) compared with the paroxetine group (20.3, P = 0.048). No significant differences were observed in the number of early discontinuations and overall TEAE. However, significantly greater proportions of patients in the duloxetine group experienced nausea and palpitations. No clinically relevant changes in laboratory values, vital signs, weight or electrocardiograms were observed with either treatment. The present study verifies the utility of duloxetine as an efficacious and safe treatment for both emotional and physical symptoms of MDD in this predominantly Asian patient sample.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17472599     DOI: 10.1111/j.1440-1819.2007.01666.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  20 in total

1.  Impact of pretreatment with antidepressants on the efficacy of duloxetine in terms of mood symptoms and functioning: an analysis of 15 pooled major depressive disorder studies.

Authors:  Bruno R Barros; Alexander Schacht; Michael Happich; Foula Televantou; Lovisa Berggren; Daniel J Walker; Hector J Dueñas
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-02

Review 2.  Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.

Authors:  Ai Leng Khoo; Hui Jun Zhou; Monica Teng; Liang Lin; Ying Jiao Zhao; Lay Beng Soh; Yee Ming Mok; Boon Peng Lim; Kok Peng Gwee
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial.

Authors:  David C Mohr; Joyce Ho; Jenna Duffecy; Douglas Reifler; Leslie Sokol; Michelle Nicole Burns; Ling Jin; Juned Siddique
Journal:  JAMA       Date:  2012-06-06       Impact factor: 56.272

Review 4.  Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis.

Authors:  Barbara Nussbaumer; Laura C Morgan; Ursula Reichenpfader; Amy Greenblatt; Richard A Hansen; Megan Van Noord; Linda Lux; Bradley N Gaynes; Gerald Gartlehner
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

5.  Prediction of response within the first 3 days to treatment with paroxetine for depression.

Authors:  Takuji Inagaki; Motohide Furuya; Tetsuya Kawamukai; Shihoh Okazaki; Hideaki Yasuda; Maiko Hayashida; Tsuyoshi Miyaoka; Akira Nishida; Jun Horiguchi
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

6.  Association between Painful Physical Symptoms and Clinical Outcomes in Korean Patients with Major Depressive Disorder: A Three-Month Observational Study.

Authors:  Min Soo Lee; Sun Young Yum; Jin Pyo Hong; Se Chang Yoon; Jai Sung Noh; Kwang Hun Lee; Jung Ki Kim; Sang Yeol Lee; Pritibha Singh; Tamas Treuer; Victoria Reed; Joel Raskin
Journal:  Psychiatry Investig       Date:  2009-12-08       Impact factor: 2.505

Review 7.  Duloxetine versus other anti-depressive agents for depression.

Authors:  Andrea Cipriani; Markus Koesters; Toshi A Furukawa; Michela Nosè; Marianna Purgato; Ichiro M Omori; Carlotta Trespidi; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 8.  The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis.

Authors:  Gerald Gartlehner; Kylie Thaler; Richard A Hansen; Bradley N Gaynes
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.

Authors:  Bret R Rutherford; Timothy M Cooper; Amanda Persaud; Patrick J Brown; Joel R Sneed; Steven P Roose
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

10.  Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial.

Authors:  Arash Mowla; Seyed Ali Dastgheib; Leila Razeghian Jahromi
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.